“Low-Dose Antithymocyte Globulin May Delay Type 1 Diabetes Progression in Children: A Small Study Suggests Further Investigation”

https://pubmed.ncbi.nlm.nih.gov/38117469

The abstract reports a small study suggesting that low-dose antithymocyte globulin may delay progression to stage 3 type 1 diabetes in some children with stage 2 disease, and warrant further investigation in prospective studies.